Medable’s AI Clinical Monitoring Agent has done what drug developers have wanted for years. It cut millions from trial budgets and sped up timelines. That’s the finding from a new independent review by the Tufts Center for the Study of Drug Development (CSDD).
According to a recent industry analysis, 89% of clinical trials eventually meet their enrollment targets, but typically take nearly twice as long as originally planned, highlighting the need for digital solutions to accelerate recruitment and monitoring.
Did the AI actually work? Medable’s Chief Medical Officer, Pamela Tenaerts, said the company needed proof. “It felt like it would make sense that that would be a benefit, but until you test it and run it, you don't know,” she said. So Medable asked Tufts CSDD for an outside, data-driven answer.
Ken Getz, executive director at Tufts, led the research. His team compared Medable’s AI agent to five years of real-world oncology trial data. They picked oncology because it’s intense and shows wider R&D trends. Getz said the same approach could work in other diseases if the data is there. The review, which is not yet peer-reviewed, looked at both direct and risk-adjusted financial effects.
The MRCT Center has published a comprehensive resource on proportionate oversight in decentralized clinical trials, providing clear guidance on monitoring participants between visits and offering practical scenarios, including responses to nine typical situations.
Getz said the real impact could be even bigger. Some benefits, like a drug gaining new uses or reaching more patients, are hard to measure but could boost returns further. The team plans to submit a peer-reviewed paper by mid-October.
For Tenaerts and Getz, the key is hard data. “For the first time there's actually an empirical study that shows this can help,” Tenaerts said. Getz agreed. He stressed the study’s careful, conservative approach. “We know that this is something that the industry has been waiting for.”
This shift goes beyond Medable. Clinical trials are getting more complex and crowded. Automating oversight without losing quality is now a must. Oncology leads drug development, with more targeted therapies and trial activity. Our recent breakdown of B cell non Hodgkin lymphoma pipelines shows this trend. Medable’s AI agent is more than a cost cutter. It’s a tool for sponsors who want to move faster than rivals and get therapies to patients sooner.
The industry now faces a turning point. Relying only on human monitors is fading. AI-driven automation, backed by real data and careful modeling, is no longer just a theory. It works. Drug developers who ignore this risk falling behind as timelines shrink and margins get tighter. The Tufts analysis sends a clear message. Results, not hype, will decide who wins the next era of clinical trials.
